HIV-1 subtype A infection in a community of intravenous drug users in Pakistan by Khan, Saeed et al.
eCommons@AKU
Department of Biological & Biomedical Sciences Medical College, Pakistan
January 2006
HIV-1 subtype A infection in a community of
intravenous drug users in Pakistan
Saeed Khan
Aga Khan University
Mohammad A. Rai
Aga Khan University
Mohammad R. Khanani
Muhammad N. Khan
Aga Khan University
Syed H. Ali
Aga Khan University
Follow this and additional works at: https://ecommons.aku.edu/pakistan_fhs_mc_bbs
Part of the Biochemistry Commons
Recommended Citation
Khan, S., Rai, M. A., Khanani, M. R., Khan, M. N., Ali, S. H. (2006). HIV-1 subtype A infection in a community of intravenous drug
users in Pakistan. BMC Infectious Diseases, 6, 164.
Available at: https://ecommons.aku.edu/pakistan_fhs_mc_bbs/509
BioMed Central
Page 1 of 6
(page number not for citation purposes)
BMC Infectious Diseases
Open AccessResearch article
HIV-1 subtype A infection in a community of intravenous drug users 
in Pakistan
Saeed Khan1, Mohammad A Rai1, Mohammad R Khanani2, 
Muhammad N Khan1 and Syed H Ali*1
Address: 1Department of Biological and Biomedical Sciences, Aga Khan University, Karachi, Pakistan and 2Dow University of Health Sciences, 
Karachi, Pakistan
Email: Saeed Khan - syed.ali@aku.edu; Mohammad A Rai - syed.ali@aku.edu; Mohammad R Khanani - syed.ali@aku.edu; 
Muhammad N Khan - syed.ali@aku.edu; Syed H Ali* - syed.ali@aku.edu
* Corresponding author    
Abstract
Background: Data on the subtypes of HIV in a population help in predicting the potential foci of
epidemic, tracking the routes of infection and following the patterns of the virus' genetic
divergence. Globally, the most prevalent HIV infection is the HIV-1 subtype C. In Asia, predominant
subtypes of HIV-1 are B, C, and CRF-01AE. During the last few years, HIV prevalence in Pakistan
has taken the form of a concentrated epidemic in at least two high risk groups, namely, Intravenous
Drug Users (IDUs) and Male Sex Workers (MSWs). Factors that have facilitated the proliferation
of HIV infection include transmission through a large number of repatriates and needle-sharing
intravenous drug users, unscreened blood transfusions, and sexual illiteracy. The HIV subtypes
infecting Pakistani populations have not been explored to date. In this study, we analyzed HIV-1
subtypes from in a high-risk community of IDUs in Karachi, the largest city of Pakistan.
Methods: Samples were collected from 34 IDUs after their informed consent. In addition, the
study subjects were administered a questionnaire regarding their sexual behavior and travel
history. For HIV analysis, DNA was extracted from the samples and analyzed for HIV types and
subtypes using subtype-specific primers in a nested polymerase chain reaction (PCR). The results
from this PCR were further confirmed using the Heteroduplex Mobility Assay (HMA).
Results: We found HIV-1 subtype A in all the 34 samples analyzed. A few of the study subjects
were found to have a history of travel and stay in the United Arab Emirates. The same subjects also
admitted to having contact with commercial sex workers during their stay abroad.
Conclusion: Our study therefore shows clade A HIV-1 to be prevalent among the IDUs in
Karachi. As the prevalence of HIV in Pakistan continues to rise, more work needs to be done to
track the infection, and to analyze the strains of HIV spreading through the country.
Background
HIV-1, the globally prevalent type of HIV, is characterized
by high genetic variability and is classified into three
groups, M, O, and N. Group M strains show the highest
worldwide distribution and currently comprise 11 sub-
types (A1, A2, B, C, D, F1, F2, G, H, J and K) and almost
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30 Circulating Recombinant Forms (CRFs). HIV subtypes
that get introduced in a community tend to spread and
evolve within that population. Consequently, HIV sub-
types show distinct geographic distribution on regional
and global levels. Knowledge of HIV-1 subtypes can there-
fore be used to understand the foci of HIV infection,
routes of its spread, as well as the patterns of the virus'
genetic divergence [1-3].
Globally speaking, Subtype A is the principal HIV-1 sub-
type found in Central and North African countries; Sub-
type B is predominant in USA, Europe, Australia, Thailand
and Brazil; Subtype C is prevalent in South Africa, Ethio-
pia and India; CRF01_AE is common in Southeast Asia
[4]. Among the Asian countries, although information on
HIV subtypes is limited, distribution of HIV subtypes
appears to remarkably diverse. In Iran, HIV-1 subtypes A
and B have been reported among, respectively, IDUs and
hemophiliacs [5]. In Uzbekistan, IDUs have been found
infected with HIV-1 subtype A as well as 03_CRFAB [6],
whereas other cases of CRF02_AG have also been reported
[7]. In Kazakastan, as well, IDUs were reported to have
HIV-1 subtype A [8]. Among the Islamic countries, Yemen
has HIV-1 subtypes A, B, C, and D, as well as some unique
recombinant forms (URFs) [9], Turkey has reported sub-
types A, B, C, D, as well as F [10]. In Lebanon, subtypes of
both HIV-1 (subtypes A, B, C, D, and G) and HIV-2 (sub-
type B) have been reported [11].
In Pakistan, no HIV subtyping data is available so far. In
terms of HIV infection, Pakistan is a high-risk, low-preva-
lence country, now with pockets of concentrated epidem-
ics in certain high risk groups. HIV high-risk populations
in Pakistan include intra- and inter-continental migrants,
commercial sex workers (including male sex workers),
people involved in unprotected intercourse, and individ-
uals exposed to contaminated needles through drug users
and/or at informal health-care facilities [12-15]. Among
these high-risk groups, the highest prevalence, respec-
tively, 26% and 7%, has been recorded among IDUs and
MSWs (personal communication).
The study presented here is the first attempt to investigate
the HIV-1 subtypes prevalent in Pakistan. For this study,
we analyzed a community of IDUs residing in central
Karachi, Pakistan, and representing similar racial and cul-
tural background. According to certain estimates, in the
year 2002, there were 500,000 heroin users in Pakistan, of
which 60,000 were thought to be injectors [16]. As nee-
dle-sharing in such groups of IDUs is a common practice,
it is logical to assume that they have infected each other
with HIV. Furthermore, it may be rationalized that the
HIV subtypes circulating among these IDUs derive from
the same ancestral strain(s). To investigate the modes of
HIV transmission in this community we administered a
questionnaire among the subjects, investigating their sex-
ual and travel history. To analyze the HIV subtypes, PCR
analysis was performed, using subtype-specific primers on
DNA extracted from blood. The subtyping results were
further confirmed by using Heteroduplex Mobility Assay
(HMA).
Methods
a) Collection of samples and subject history
The study was approved by the Internal Review Board of
Aga Khan University, Karachi. HIV-1 positive patients
were selected from a community of IDUs. 2–3 ml of
whole blood was collected from these subjects with their
prior oral/verbal informed consent. For all of the subjects
studied, HIV-1 status was previously known to be posi-
tive, based on their HIV antibody tests. The subjects were
also asked to volunteer information regarding behavior
considered high risk for HIV infection. Additionally, the
subjects were interviewed about their travel history out-
side of Pakistan.
b) Extraction of DNA (cellular and viral)
To 0.5 ml of whole blood, 0.9 ml of 1X RBC lysing solu-
tion (0.32 M Sucrose, 1 % Triton X-100, 5 mM MgCl2.6
H2O, 12 mM Tris- HCl, pH 7.6) was added and centri-
fuged at 13000 rpm for 1 min. The supernatant was dis-
carded and the pellet was re-extracted with 0.9 ml RBC
lysing solution. After centrifugation at 13,000 rpm, the
pellet was washed with 1 ml water and allowed to dry. To
the dried pellet, 20 μl 20 % SDS, 80 μl Proteinase K buffer
(0.375 M NaCl, 0.12 M EDTA, pH 8.0) and 40 μl of 10
mg/ml Proteinase K was added to the solution was incu-
bated at 55°C for 1 hour. Subsequently, 100 μl of 6 M
NaCl was added to the sample and centrifugation was car-
ried out for 5 min at 13000 rpm. Supernatant was then
transferred to a fresh tube and added with 1 ml 100% eth-
anol. DNA was then pellet by centrifugation at 13000 rpm
for 5 min. The DNA pellet was washed with 70% ethanol,
air-dried, re-suspended in 50 μl of 1X TE buffer, and
stored at -20°C.
c) PCR analysis
β-globin PCR
As a control for DNA extraction, β-globin PCR was done
with PC03 and PC04 primers (Table 1). The final 25 μl
PCR mixture contained 5 μl of sample, 1X PCR buffer (10
mM Tris-HCl, pH9.0, 50 mM KCl, 0.1 % Triton X-100), 1
mM MgCl2, 200 μM of dNTPs, 0.2 pmol of each primer,
and 0.2 U of Taq Polymerase. Thermocycling conditions
were 94°C for 5 min; 40 cycles of 94°C for 30 sec, 51°C
for 30 sec, 72°C for 30 sec; 72°C for 5 min.
Nested PCR for HIV-1 subtyping
PCR was performed to confirm HIV-1 infection and to
analyze the subtypes. PCR was performed as described by
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Kato, et al. [4], to distinguish subtypes A, B, C, and CRF01-
AE in the env C2V3C3 region.
Cell-associated env V3 viral DNA sequences were ampli-
fied by nested PCR as follows: The reaction mixture of 25
μl for both first and second round PCR contained 10 mM
Tris-HCl, pH9.0, 50 mM KCl, 0.1 % Triton X-100, 1.5 mM
MgCl2, 200 μM dNTPs, and 0.25 U of Taq Polymerase. The
first round PCR was performed with 0.5 μM of primers
JA9AE, JA9B, JA12A and JA12B (Table 1). Thrermocycling
conditions were 94°C for 5 min; 30 cycles of 94°C for 15
sec, 56°C for 30 sec, 72°C for 60 sec; 72°C for 5 min.
1 μl of the first-round PCR product was used in each sec-
ond-round PCR. Upstream primers used were a mixture of
0.33 μM each of JA10UB, JA10UC, and JA10UG (Table 1).
Downstream primers used were different for each reac-
tion. For subtype-independent amplification, a mixture of
three primers was used, namely, 0.33 μM each of
JA11LAE, JA11LB, and JA11LC. For subtype A 1 μM
JA11QA; for subtype B, 1 μM JA11VB; for subtype C, 1 μM
JA11XC, and for CRF01-AE, 1 μM JA11YE. Thermocycling
conditions for the second round was 94°C for 5 min; 30
cycles of 94°C for 15 sec, 60°C for 30 sec, 72°C for 60 sec;
72°C for 5 min. The amplified products were detected on
a 2% agarose gel and visualized by ethidium bromide
staining.
A particular subtype was assigned to a sample if that sub-
type-specific reaction produced a band higher than 20%
in intensity of the band produced by the subtype-inde-
pendent reaction [4].
Heteroduplex Mobility Assay (HMA)
To confirm the results obtained from PCR we used Heter-
oduplex Mobility Assay (HMA)[17]. The assay was per-
formed using a kit from the NIH AIDS Research and
Reference Reagent Program (Rockville, MD, USA). The
HMA was performed for the HIV-1 gag region, according
to the protocol provided with the kit. For some selected
samples, we further confirmed our results thorough
another HMA for the env region. These confirmatory
HMAs were independently performed at James I. Mullins'
laboratory at the University of Washington School of
Medicine, Seattle, USA. For gag HMA, nested PCR was
used to amplify 1.121 kb and then 0.448 kb internal frag-
ment of the HIV-1 Gag encoding region from both the
uncharacterized sample and known reference strain.
Primers HIG777 and H1P0202 were used in the first
round while H1Gag1584 and g17 were used in the second
round PCR (Table 1).
Upon completion of PCR, 4.5 μl the gag reference ampli-
con was mixed with 4.5 μl of gag amplicon of the
unknown sample, along with 1 μl of 10X Heteroduplex
annealing buffer (1 M NaCl, 20 mM EDTA,100 mM
Tris.HCl pH7.8). The mixture was heated at 95°C for 2
minutes, followed by rapid cooling on ice. 3 μl loading
dye was added to the mix and ran on 5% polyacrylamide
containing 20% urea, for 3–4 hours at 250 V. Subse-
quently, the gel was stained with ethidium bromide and
DNA bands visualized by UV illumination.
Results
We have analyzed subtypes of HIV-1 in a group of HIV-1
positive IDUs using two different techniques, i.e., sub-
type-specific PCR (Fig. 1) and HMA (Fig. 2). Blood sam-
ples from 34 HIV positive subjects were analyzed for this
study and they were all found to have HIV-1 subtype A
(Figs. 1&2). Some of the IDU subjects had a history of
travel and prolonged stay abroad, and of sexual contact
with commercial sex workers during their stay abroad
(Table 2).
Discussion
The work presented here is the first report on the prevalent
subtypes of HIV in Pakistan. Since the official recognition
of the first case of an HIV infected individual in 1986 in
Pakistan [18], the number of persons infected with HIV
Table 1: List of primers employed in the study.
Primer Sequence
PC03 ACACAACTGTGTTCACTAGC
PC04 CAACTTCATCCACGTTCACC
JA9AE CACAGTACAATGCACACATG
JA9B CACAGTACAATGTACACATG
JA12A GCAATAGAAAAATTCTCCTC
JA12B ACAGTAGAAAAATTCCCCTC
JA10UB CTGTTAAATGGCAGTCTAGC
JA10UC CTGTTAAATGGTAGTCTAGC
JA10UG CTGTTAAATGGCAGTTTAGC
JA11LAE AATTTCTAGATCCCCTCCTG
JA11LB AATTTCTGGGTCCCCTCCTG
JA11LC AATTTCTAGGTCCCCTCCTG
JA11QA CCCCTCCTGAGGAGTTAGCA
JA11VB CACAATTAAAACTGTGCATTACAA
JA11XC TTGTTTTATTAGGGAAGTGTTC
JA11YE AAATTCCCCTCTACAATTAAAATGA
Primers used in gag HMA
HIG777 TCACCTAGAACTTTGAATGCATGGG
H1P0202 CTAATACTGTATCATCTGCTCCTGT
H1Gag1584 AAAGATGGATAATCCTGGG
g17 TCCACATTTCCAACAGCCCTTTT
PC03/PC04 primers for β-Globin, JA9AE, JA9B are the upstream 
primers and JA12A, JA12B are the downstream primer for the first 
round PCR. JA10UB, JA10UC and JA10UG are the inner upstream 
primers; JA11LAE, JA11LB and JA11LC are the inner downstream 
general primers. JA11QA, JA11VB, JA11XC and JA11YE are the inner 
downstream subtype specific primers for subtypes A, B, C and 
CRF01-AE, respectively.
Primers for gag HMA are relative to HIV-1 group M strain ELI 
(GenBank accession number K03454)
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and/or AIDS has been constantly on the rise. Being an
underdeveloped country with low (sexual) literacy rate,
Pakistan is thought to have an overwhelming number of
risk factors, including gender bias, poverty, substandard
healthcare, and prevailing social taboos on sexual aware-
ness (16) that may contribute to the spread of HIV in the
country. Thus, due to the low number of reported cases
but a high degree of risk factors, Pakistan is considered a
low prevalence yet high-risk country. There have been
reported outbreaks of viral infections, including HIV
[19,20], in various pockets of Pakistan. No attempts have
yet been made, however, to track the origin of infection,
or to monitor its spread.
One way of tracking a viral infection is by establishing the
epidemiology of its subtypes. This kind of study, however,
has not so far been undertaken in Pakistan. Consequently,
it is all a matter of speculation when it comes to identify-
ing the sources of infection outbreaks. Understandably,
therefore, well-intentioned attempts at screening and/or
prevention of HIV are rendered ineffective due to a lack of
pin-pointed focus.
Demography of HIV high risk groups in Pakistan is typical
of many other countries, with the highest prevalence of
HIV found among sex workers, needle-sharing drug
addicts, and recipients of unscreened blood products [21].
In the last few years, however, HIV prevalence has gradu-
ally risen among the IDUs [19,22-28]. Our communica-
tion with the HIV Surveillance Centers in the country
reveals that the prevalence of HIV infection in the com-
munity of IDUs (mainly located in the central city of Kara-
chi) has risen to 26%. This upgrades the occurrence of HIV
in IDUs from low prevalence to a concentrated epidemic.
Work on the analysis of HIV-1 subtypes in Pakistan must
continue. As data on HIV subtypes in the neighboring
Asian countries [5-8], and Islamic countries in Europe
[10] and Middle East [9,11] start to accumulate, patterns
of viral spread and divergence are beginning to emerge. In
Representative gel of subtype-specific PCR for HIV-1Figure 1
Representative gel of subtype-specific PCR for HIV-1. Symbols indicate the primers used: Bg; β-globin. H; subtype-independent 
PCR for HIV-1; A, B, C; respectively, HIV-1 subypes A, B and C. The first and last lanes represent 50 bp molecular weight lad-
der. Two panels are shown, i.e., PCR amplification from known HIV positive and HIV negative subjects. In the HIV negative 
subject, only the β-globin gene was amplified. In the HIV positive sample, products were observed for subtype-independent 
(H), and HIV-1 subtype A specific PCR. A faint band is observed in lane B, but, as explained in Material and Methods, this band 
was disregarded due to its significantly low intensity as compared to the band in H (and A).
HIV  Positive Sample HIV Negative Sample        
50bp   Bg H      A      B      C      Bg H      A      B      C    50bp 
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the long run, subtype data on HIV will be tremendously
useful for determining the right treatment and prevention
strategies as well as in designing vaccine trials, when an
HIV vaccine becomes available.
Conclusion
With the work reported here, we have initiated fundamen-
tal groundwork that shall lead to more educated attempts
at prevention and control of HIV infection in Pakistan. As
the prevalence of HIV in Pakistan continues to rise, the
need to identify, quantify, and track the virus in high-risk
communities warrants urgency.
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